BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 36942903)

  • 1. CT-guided
    Chen Z; Fu X; Qiu Z; Mu M; Jiang W; Wang G; Zhong Z; Qi H; Gao F
    Radiol Oncol; 2023 Mar; 57(1):127-139. PubMed ID: 36942903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: A propensity score matching analysis.
    Shuanggang C; Shen L; Qiu Z; Qi H; Cao F; Xie L; Fan W
    J Cancer Res Ther; 2020; 16(2):250-257. PubMed ID: 32474509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial chemoembolization combined with microwave ablation versus microwave ablation only for Barcelona clinic liver cancer Stage B hepatocellular carcinoma: A propensity score matching study.
    Li X; Chen B; An C; Cheng Z; Han Z; Liu F; Yu J; Liang P
    J Cancer Res Ther; 2020 Sep; 16(5):1027-1037. PubMed ID: 33004744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of step-by-step debulking microwave ablation for huge unresectable hepatocellular carcinoma patients after transcatheter arterial chemoembolization refractoriness.
    Huang T; Qi H; Shen L; Wu Y; Song Z; Cao F; Liu Y; Xie L; Chen S; Tang T; Li H; Zhang Y; Feng L; Zhang H; Chen J; Fan W
    Int J Hyperthermia; 2022; 39(1):935-945. PubMed ID: 35853727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis.
    Chen S; Shi M; Shen L; Qi H; Wan W; Cao F; Xie L; Wu Y; Chen G; Mo J; Zhu G; Ye D; Zhang Y; Feng Z; Xu L; Fan W
    Int J Hyperthermia; 2020; 37(1):384-391. PubMed ID: 32323585
    [No Abstract]   [Full Text] [Related]  

  • 6. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
    Ni JY; Fang ZT; Sun HL; An C; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
    Eur Radiol; 2020 Apr; 30(4):2377-2390. PubMed ID: 31900694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial Chemoembolization Monotherapy Versus Combined Transarterial Chemoembolization-Microwave Ablation Therapy for Hepatocellular Carcinoma Tumors ≤5 cm: A Propensity Analysis at a Single Center.
    Chen QF; Jia ZY; Yang ZQ; Fan WL; Shi HB
    Cardiovasc Intervent Radiol; 2017 Nov; 40(11):1748-1755. PubMed ID: 28681222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
    Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
    World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Efficacy and Safety of TACE Combined with Microwave Ablation and TACE Combined with Cryoablation in the Treatment of Large Hepatocellular Carcinoma.
    Wang Y; Li W; Man W; Dong X; Luo Y; Zhang Y; Zhang Y; Dong C; Sun W; Yang P
    Comput Intell Neurosci; 2022; 2022():9783113. PubMed ID: 35795769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma.
    Zhang R; Shen L; Zhao L; Guan Z; Chen Q; Li W
    Diagn Interv Radiol; 2018 Jul; 24(4):219-224. PubMed ID: 29792289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.
    Zhang ZH; Liu QX; Zhang W; Ma JQ; Wang JH; Luo JJ; Liu LX; Yan ZP
    World J Gastroenterol; 2017 Nov; 23(43):7735-7745. PubMed ID: 29209114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance.
    Shi Q; Zhou X; Zhang Z; Zhang W; Ma J; Yang M; Yu J; Luo J; Liu L; Yan Z
    Front Immunol; 2022; 13():1097625. PubMed ID: 36703965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
    Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
    BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas.
    Zheng L; Li HL; Guo CY; Luo SX
    Korean J Radiol; 2018; 19(2):237-246. PubMed ID: 29520181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single medium-sized hepatocellular carcinoma treated with sequential conventional transarterial chemoembolization (cTACE) and microwave ablation at 4 weeks versus cTACE alone: a propensity score.
    Zhu ZY; Yuan M; Yang PP; Xie B; Wei JZ; Qin ZQ; Qian Z; Wang ZY; Fan LF; Qian JY; Tan YL
    World J Surg Oncol; 2022 Jun; 20(1):192. PubMed ID: 35689233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-eluting bead trans-arterial chemoembolization combined with microwave ablation therapy vs. microwave ablation alone for early stage hepatocellular carcinoma: a preliminary investigation of clinical value.
    Liu J; Zhang W; Lu H; Li H; Zhou X; Li J; Han X
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1781-1788. PubMed ID: 34405295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis.
    Yang Y; Yu H; Qi L; Liu C; Feng Y; Qi J; Li J; Zhu Q
    Int J Hyperthermia; 2022; 39(1):455-465. PubMed ID: 35271786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CT-guided High-Dose-Rate Brachytherapy versus Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma.
    Auer TA; Müller L; Schulze D; Anhamm M; Bettinger D; Steinle V; Haubold J; Zopfs D; Pinto Dos Santos D; Eisenblätter M; Gebauer B; Kloeckner R; Collettini F
    Radiology; 2024 Feb; 310(2):e232044. PubMed ID: 38319166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.